Project Grant R01DK139200

Award Date 7/2/24
Completion Date 6/30/26
Dollars Obligated $1.2M
Federal Grant Program
93.847
Assistance Type
Project Grant
Place of Performance
Sacramento, CA 95817, USA
Similar Awards
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,331,148 to Yale University to investigate the mechanisms by which pancreatic alpha cells compensate for beta cell mass deficiency in type 2 diabetes. The research aims to determine the signaling pathways and adaptations that allow alpha cells to increase glucagon secretion in a...
This $205,280.00 Project Grant awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research to improve understanding of the mechanisms driving the differences in insulin secretion responses between the two incretin receptors, glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR), in pancreatic beta...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $208,428 to The Regents of the University of California, San Francisco to enhance the safety and efficacy of stem cell-derived islet transplantation for treating type 1 diabetes. The key products or services to be delivered under this award include: 1) Improving the engraftment and...
This federal Project Grant award of $577,694 from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate the mechanisms underlying Type 3C diabetes (T3CD) associated with exocrine pancreas diseases like chronic pancreatitis and pancreatic ductal adenocarcinoma. The key objectives are to: 1) study gene regulation and electrophysiology in primary human islet cells from subjects with...
This $1,349,491 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports research to uncover the mechanisms by which the transaminase GPT2 promotes pancreatic beta cell dysfunction and death. The key objectives are to: 1) Determine how GPT2 affects mitochondrial function, metabolism, and epigenetics in beta cells under metabolic stress; and 2)...
This $288,980 federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) will support research to investigate the mechanisms of beta and delta cell coordination within pancreatic islets under high glucose conditions. The award to the University of California, Davis aims to definitively establish the predominant mechanisms, whether paracrine signaling...
This $698,646 federal Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant aims to study the functional and disease relevance of distinct pancreatic beta-cell subtypes, with a focus on understanding their epigenetic regulation and relationship to type 2 diabetes (T2D). The research will use novel single-cell epigenomic tools, conditional...
This $267,310 Project Grant was awarded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The grant supports research to investigate the role of G protein-coupled estrogen receptor (GPER) signaling in maintaining beta cell identity and function, and its relationship to store-operated calcium entry (SOCE) in the context of type 2 diabetes pathogenesis. The research aims to...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) provides $194,616 to Weill Medical College of Cornell University to investigate the impact of activating the transcription factor ATF6 in pancreatic beta cells. The research aims to examine how constitutive activation of ATF6 affects insulin production and secretion in beta cells,...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under CFDA Program 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research, provides $1,041,906 to the Regents of the University of Michigan to investigate the role and mechanism of the protein UNC119B in regulating glucose homeostasis. The key objectives are to: 1) examine the importance of UNC119B in glucose storage tissues for maintaining glucose homeostasis; 2) determine if...

14-3-3-ZETA REGULATION OF ISLET HEALTH - ENTER THE TEXT HERE THAT IS THE NEW ABSTRACT INFORMATION FOR YOUR APPLICATION. THIS SECTION MUST BE NO LONGER THAN 30 LINES OF TEXT. PANCREATIC ISLET DYSFUNCTION IS CENTRAL TO TYPE 2 DIABETES MELLITUS (T2DM) PATHOGENESIS AND CONSISTS OF BOTH A-CELL AND B-CELL DYSFUNCTION. THE REGULATION OF A-CELL AND B-CELL HEALTH IS DETERMINED BY A COMPLEX NETWORK OF PARACRINE REGULATORS THAT ARE INCOMPLETELY DEFINED. TO IMPROVE THE TREATMENT AND PREVENTION OF T2DM, IT IS CRITICAL TO HAVE A COMPLETE PICTURE OF A-CELL AND B-CELL REGULATION. WE HAVE IDENTIFIED THE SIGNALING PROTEIN, 14-3-3Z, AS AN IMPORTANT REGULATOR OF B-CELL FUNCTION AND CROSSTALK BETWEEN A-CELLS AND B-CELLS. SPECIFICALLY, RECENT WORK FROM OUR LAB DEMONSTRATES THAT B-CELL 14-3-3Z INHIBITION INCREASES GLUCOSE-STIMULATED INSULIN SECRETION (GSIS) AND ACTIVATES A-CELL ACTIVE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) PRODUCTION AND SECRETION IN MOUSE AND HUMAN ISLETS. IT IS INCREASINGLY EVIDENT THAT A-CELLS PLAY AN IMPORTANT ROLE IN THE POTENTIATION OF GSIS, THEREBY EXPANDING THEIR FUNCTION BEYOND THAT OF THE TRADITIONAL COUNTERREGULATORY ROLE. EFFORTS TO UNDERSTAND THE ROLE OF THE A-CELL IN THE REGULATION OF ISLET FUNCTION HAVE REVEALED BOTH TRANSCRIPTIONAL AND FUNCTIONAL HETEROGENEITY. FURTHER ANALYSIS OF THIS HETEROGENEITY SUGGESTS THAT FUNCTIONALLY DISTINCT A-CELL SUBPOPULATIONS DISPLAY ALTERATIONS IN THEIR HORMONE PROFILE, WITH SOME A-CELLS PRODUCING ACTIVE GLP-1 FROM THE PROGLUCAGON PRECURSOR. WHILE GLP-1 AND GLUCAGON ARE BOTH ABLE TO POTENTIATE GSIS VIA LOCAL ACTIONS MEDIATED BY GLP-1R AND GLUCAGON RECEPTOR EXPRESSED BY B-CELLS, ONLY GLUCAGON STIMULATES HEPATIC GLUCOSE PRODUCTION (HGP). IN EFFECT THEN BY SWITCHING THEIR ENDOCRINE OUTPUT FROM GLUCAGON TO GLP-1, A-CELLS FAVOR GSIS OVER THE STIMULATION OF HGP. HOW PLASTICITY IN A-CELL ENDOCRINE PROFILE IS REGULATED AND HOW IT IMPACTS OVERALL ISLET FUNCTION IS UNKNOWN. THEREFORE, WE WILL TEST THE HYPOTHESIS THAT B-CELL 14-3-3Z REGULATES GSIS BY ENHANCING A-CELL TO B-CELL CROSSTALK. AIM 1 WILL DETERMINE THE ROLE OF A-CELL GLP-1 IN 14-3-3Z REGULATION OF ISLET FUNCTION. TO THIS END, WE WILL ASSESS GSIS IN RESPONSE TO B-CELL 14-3-3Z INHIBITION IN ISLETS FROM WILD-TYPE MICE AND MICE WITH A-CELL-SPECIFIC INABILITY TO PRODUCE GLP-1. AIM 2 WILL DEFINE THE REGULATION OF PLASTICITY IN A-CELL HORMONE PRODUCTION BY B-CELL 14-3-3Z. TO THIS END, WE WILL DEFINE THE REGULATION OF GLP-1+ A-CELLS INDUCED BY B-CELL 14-3-3Z ABLATION AND DETERMINE THE RECEPTOR CLASS RESPONSIBLE FOR ACTIVATION OF A-CELL GLP-1 PRODUCTION.

Posted 7/2/24, 12:00 AM